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Background: Prospective studies in non-Mediterranean populations have consistently related increasing nut
consumption to lower coronary heart disease mortality. A small protective effect on all-cause and cancer mortality
has also been suggested. To examine the association between frequency of nut consumption and mortality in
individuals at high cardiovascular risk from Spain, a Mediterranean country with a relatively high average nut intake
per person.
Methods: We evaluated 7,216 men and women aged 55 to 80 years randomized to 1 of 3 interventions
(Mediterranean diets supplemented with nuts or olive oil and control diet) in the PREDIMED (‘PREvención con DIeta
MEDiterránea’) study. Nut consumption was assessed at baseline and mortality was ascertained by medical records
and linkage to the National Death Index. Multivariable-adjusted Cox regression and multivariable analyses with
generalized estimating equation models were used to assess the association between yearly repeated
measurements of nut consumption and mortality.
Results: During a median follow-up of 4.8 years, 323 total deaths, 81 cardiovascular deaths and 130 cancer deaths
occurred. Nut consumption was associated with a significantly reduced risk of all-cause mortality (P for trend <0.05, all).
Compared to non-consumers, subjects consuming nuts >3 servings/week (32% of the cohort) had a 39% lower
mortality risk (hazard ratio (HR) 0.61; 95% CI 0.45 to 0.83). A similar protective effect against cardiovascular and
cancer mortality was observed. Participants allocated to the Mediterranean diet with nuts group who consumed
nuts >3 servings/week at baseline had the lowest total mortality risk (HR 0.37; 95% CI 0.22 to 0.66).
Conclusions: Increased frequency of nut consumption was associated with a significantly reduced risk of mortality
in a Mediterranean population at high cardiovascular risk.
Please see related commentary: http://www.biomedcentral.com/1741-7015/11/165.
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Nuts are an important component of the so-called
Mediterranean diet (MedDiet) and a good source of
unsaturated fatty acids, fiber, minerals (potassium, calcium
and magnesium), vitamins (folate and tocopherols) and
other bioactive compounds, such as phytosterols and
polyphenols [1–4].
There is consistent evidence to suggest that the con-
sumption of nuts has a beneficial effect on cardiovascular
health, and this effect is attributable to their unique nutri-
tional composition [5]. A pooled analysis of four large-scale
observational studies showed that subjects in the highest
nut consumption categories had an approximately 35%
reduced risk of incident coronary heart disease (CHD) [6].
The frequency of nut consumption was also related to
lower rates of sudden cardiac death in a large cohort of
men [7]. Furthermore, epidemiologic studies and clinical
trials have shown that frequent nut consumption is
associated with a reduced load of cardiovascular disease
risk factors, such as dyslipidemia, type 2 diabetes, and
metabolic syndrome [4,6,8,9]. In addition, reports from
the Iowa Women’s Health study [10], a large Dutch cohort
[11], and the US Nurses’ Health Study [12], which assessed
populations with relatively low overall nut intake, suggested
that frequent nut consumption related inversely to
total mortality, albeit the protective effect was weak,
with adjusted risk reductions ranging from 5% to 15%
[10–12]. If an inverse association between nut con-
sumption and all-cause mortality exists, the beneficial
effect might be more robust in Mediterranean regions,
where nut consumption per person is relatively high
compared to other countries [13].
The main aim of the PREDIMED study was to test the
efficacy of two Mediterranean diets (one supplemented
with extra-virgin olive oil and another with nuts), as
compared to a control diet (advice on a low-fat diet), on
primary cardiovascular prevention. In contrast, in this
current manuscript our aims were only to assess the
association between baseline consumption of nuts
(that is, the consumption of nuts previous to starting the
intervention) and total mortality (instead of cardiovascular
events). We have additionally included the repeated
measurements for the consumption of nuts during follow-
up as another exposure, regardless of the allocated arm of
the trial; this is in contrast with the original PREDIMED
study, which used an intention-to-treat analysis.
We hypothesized that level of nut consumption would
be strongly associated with mortality in the cohort of
the PREDIMED (‘PREvención con DIeta MEDiterránea’)
study, including older men and women at high cardio-
vascular risk [14]. To this end, in this cohort we longitu-
dinally examined the association between the frequency
of nut consumption at baseline and the risk of mortality
at the end of follow-up.Methods
Study population
The present study was conducted within the framework of
the PREDIMED trial, the design of which has been
described in detail elsewhere [14]. Briefly, the PREDIMED
study is a large, multicenter, parallel-group, randomized
and controlled clinical trial for the primary prevention of
cardiovascular disease (CVD) (http://www.predimed.es and
http://www.predimed.org). The main results of the trial on
the primary endpoint have been recently published [15].
We assigned 7,447 older participants (men aged 55 to 80
years and women 60 to 80 years) to 1 of 3 interventions:
a MedDiet enriched with extra-virgin olive oil (EVOO),
a MedDiet supplemented with mixed nuts, or advice on a
low-fat diet (control diet). Participants had no CVD at
enrollment but they were at high cardiovascular risk
because of the presence of type 2 diabetes or at least
three of the following risk factors: current smoking,
hypertension, hypercholesterolemia, low high-density
lipoprotein (HDL)-cholesterol, overweight or obesity,
and family history of premature CVD. Exclusion criteria
were the presence of severe medical condition that may
impair the ability of the person to participate in a nutrition
intervention study (for example, digestive disease with
fat intolerance, advanced malignancy, or major neuro-
logical, psychiatric or endocrine disease), immunodeficiency
or HIV positive status, alcohol or drug abuse, body mass
index (BMI) ≥40 kg/m2, and allergy or intolerance to olive
oil or nuts [16].
The primary endpoint of the main trial is a combination
of several cardiovascular events (myocardial infarction,
stroke or cardiovascular death). The present study was
conducted as an observational cohort using baseline
consumption of nuts as the exposure. The outcomes
were: (1) total mortality, (2) only cardiovascular mortality,
and (3) only cancer mortality. All participants provided
written informed consent according to a protocol approved
by the institutional review boards of the recruiting centers
(Comité de Ética e Investigación Clínica (CEIC) Hospital
Universitari Sant Joan de Reus, CEIC Universidad de
Navarra, CEIC Hospital Clínic de Barcelona, Comité de
Ética Universidad de Valencia, CEIC-Parc de Salut Mar,
CEIC Hospital Universitario Araba, CEIS del distrito
Sanitario Atención Primária Sevilla, IDIAP Jordi Gol,
CEIC Complejo Hospitalario Materno-Insular, CEIC
Facultad Medicina Universidad de Málaga, CEIC Illes
Balears, and CEIC Hospital Universitari Bellvitge).
Dietary assessment
At baseline trained dietitians completed a 137-item
semiquantitative food frequency questionnaire in a face-
to-face interview with the participant; this questionnaire
has been validated before in an older population at high
cardiovascular risk from Spain [17]. Energy and nutrient
Guasch-Ferré et al. BMC Medicine 2013, 11:164 Page 3 of 11
http://www.biomedcentral.com/1741-7015/11/164intake were estimated using Spanish food composition
tables [18,19]. Information on self-reported nut intake
was derived from the food frequency questionnaire. The
questionnaire includes one item regarding the consumption
of almonds, peanuts, hazelnuts, pistachios and pine nuts
(macadamias, cashews and Brazil nuts are rarely consumed
in Spain), and another question specifically inquired about
the consumption of walnuts. The dietitians asked the
participants if they consumed this food item never, between
1 to 3 times per month, times per week (1, 2 to 4, 5 to 6;
three options) or times a day (1, 2 to 3, 4 to 6, >6; four
options). For the purpose of the present study, 28 g of nuts
was considered to be one serving. Peanuts, almonds,
hazelnuts, walnuts, pine nuts, pistachios, Brazil nuts,
macadamia and cashews were all considered nuts. In
addition, dietitians administered a validated 14-item
MedDiet screener designed to assess the degree of
adherence to the traditional MedDiet [20]. We used
the score of this brief screener to control for the over-
all dietary pattern, because a higher adherence to the
MedDiet among frequent consumers of nuts could
introduce confounding. For this purpose, the question
about nut consumption was omitted from the brief
screener; therefore, a 13-point score was used as a covariate
(minimum 0, maximum 13).
Ascertainment of mortality
Information on mortality was updated once a year by
the End-point Adjudication Committee, whose members
were blinded to treatment allocation. Different sources
of information were used: (1) yearly questionnaires and
examinations to all participants, (2) family physicians,
(3) yearly review of medical records, and (4) linkage to the
National Death Index. Medical records of deceased partic-
ipants were requested, and the End-point Adjudication
Committee adjudicated the cause of the death.
Assessment of other covariates
At baseline, questionnaires about lifestyle variables,
educational achievement, history of illnesses, and medica-
tion use were administered. Physical activity was assessed
using the validated Spanish version of the Minnesota
Leisure-Time Physical Activity questionnaire [21]. Partici-
pants were considered to be diabetic, hypercholesterolemic
or hypertensive if they had previously been diagnosed as
such, and/or they were being treated with antidiabetic,
cholesterol-lowering, or antihypertensive agents, respect-
ively. Trained personnel took the anthropometric and
blood pressure measurements. Weight and height were
measured with light clothing and no shoes with calibrated
scales and a wall-mounted stadiometer, respectively; waist
circumference was measured midway between the lowest
rib and the iliac crest using an anthropometric tape; blood
pressure was measured using a validated oscillometer(Omron HEM705CP; Hoofddorp, The Netherlands) in
triplicate with a 5-minute interval between each meas-
urement, and the mean of these values was recorded.
Statistical analyses
Follow-up time was calculated as the difference between
the date of either death or end of follow-up (the date of the
last visit or the last recorded clinical event of participants
still alive) and the date of recruitment. Extremes of total en-
ergy intake (>4,000 or <800 kcal per day in men and >3,500
or <500 kcal per day in women) were excluded from
the analysis [22]. Three categories of frequency of nut
consumption were considered (never or almost never,
1 to 3 servings per week and >3 servings per week). We
used analysis of variance (ANOVA) or the Pearson χ2 tests
to compare the quantitative or categorical baseline charac-
teristics of the study participants, respectively, across
servings of nut consumption. Results were expressed as
means ± SD or percentages. Because no interaction was
observed between sex and the main outcome, analyses
were conducted for men and women together.
To assess the risk of total mortality by frequency of nut
consumption, multivariate relative risks were computed
using Cox proportional hazard models, and potential con-
founders were controlled for. All analyses were stratified
by the recruitment center. Results are expressed as hazard
ratios (HRs) with 95% confidence intervals (CIs). Given
the different nutritional composition of walnuts and other
nuts [1], we performed separate analyses for the frequency
of total nut consumption, walnut consumption, and con-
sumption of nuts excluding walnuts. After the unadjusted
model, another model was adjusted for age (continuous),
sex and intervention group. Then, a second model, was
additionally adjusted for BMI (continuous), current smok-
ing status (never, former, or current smoker), educational
level (illiterate/primary education, secondary education,
academic/graduate), physical activity (MET-min/day), total
energy intake (kcal/day), history of diabetes (yes/no), history
of hypercholesterolemia (yes/no), use of oral antidiabetic
medication (yes/no), antihypertensive drugs (yes/no), and
statins (yes/no). Finally, a third, fully-adjusted model, was
additionally adjusted for alcohol intake (continuous, adding
a quadratic term), quintiles of consumption of dietary
food groups (vegetables, fruits, red meat, eggs, and fish),
and adherence to the MedDiet (13-point score). The same
models were used to assess the risk of cardiovascular
mortality or cancer mortality, also using Cox proportional
hazard models. Linear trend tests were assessed assigning
the median value to each category of nut consumption and
using it as a continuous variable in the various models. We
evaluated the interaction between baseline nut consump-
tion (three categories, two dummy variables) and the
intervention group (three groups, two dummy variables)
by introducing an interaction term with four degrees
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models to assess the risk of total mortality, cardiovas-
cular mortality and cancer mortality according to the
joint categories of total nut consumption and interven-
tion group. Linear trends were also tested. We had
yearly updated information on nut consumption, so to
take advantage of this updated information we repeated
the analysis using generalized estimating equations to
assess the association between repeated measurementsTable 1 Baseline characteristics of study participants by frequ
Variable Baselin
Never
Age, years 67 ± 6
Men, % (n) 36 (773
BMI, kg/m2 30.6 ±
Weight, kg 77.2 ±
Waist circumference, cm 101.5 ±
Leisure-time energy expenditure in physical activity, MET-min/day 195 ± 2




Educational level, % (n)
Illiterate/primary education 82 (1,74
Secondary education 12 (266
Academic/graduate 5 (112)
Diabetes, % (n) 53 (1,11
Hypertension, % (n) 83 (1,76
Hypercholesterolemia, % (n) 70 (1,47
Medication use, % (n)
Oral antidiabetic drugs 36 (760
Antihypertensive drugs 75 (1,58
Statins 48 (1,02
Modified MedDiet score (13-point score) 8.1 ± 1
Total energy intake, g/day 2,060 ±
Nuts, g/day 0
Alcohol, g/day 6.6 ± 1
Vegetables, g/day 317 ± 1
Fruit, g/day 344 ± 2
Red meat (beef, pork, lamb), g/day 70.4 ±
White meat (chicken, rabbit, turkey), g/day 44.6 ±
Eggs, g/day 19.4 ±
Fish, g/day 91.8 ±
Dairy products, g/day 387 ± 2
Data are expressed as mean ± SD or percentage (n). P value for comparisons across
one-way analysis of variance for continuous variable) as appropriate.
BMI, body mass index.of nut consumption and mortality. For each 1-year period
we used as exposure the average nut consumption of all
repeated measurements from baseline to the beginning of
that yearly period.
The level of significance for all statistical tests was
P <0.05 for bilateral contrast. Analyses were performed
using SPSS statistical software, version 19 (SPSS Inc,
Chicago, IL, USA) and STATA software, version 12.0
(Stata Corp., College Station, TX, USA).ency of nut consumption
e frequency of nut consumption





66 ± 6 67 ± 6 <0.001
) 43 (1,219) 47 (1,079) <0.001
4.0 29.9 ± 3.7 29.4 ± 3.7 <0.001
12.0 77.1 ± 12.1 75.8 ± 11.6 <0.001
10.5 100.7 ± 10.4 99.2 ± 10.0 <0.001
20 231 ± 232 264 ± 257 <0.001
<0.001
7) 61 (1,708) 59 (1,364)
) 14 (402) 12 (292)
) 24 (693) 28 (639)
<0.001
0) 76 (2,131) 75 (1,733)
) 16 (451) 16 (379)
8 (221) 8 (183)
8) 47 (1,338) 46 (1,071) <0.001
3) 83 (2,320) 82 (1,887) 0.670
9) 73 (2,044) 73 (1,689) 0.012
) 31 (884) 29 (679) <0.001
7) 72 (2,037) 71 (1,624) 0.008
2) 48 (1,364) 47 (1,093) 0.761
.7 8.2 ± 1.8 8.6 ± 1.7 <0.001
529 2,222 ± 514 2,416 ± 537 <0.001
4.9 ± 2.3 25.7 ± 14.4 <0.001
3.4 8.4 ± 13.8 9.7 ± 14.7 <0.001
44 329 ± 145 355 ± 149 <0.001
00 354 ± 195 407 ± 204 <0.001
44.3 79.1 ± 46.1 78.6 ± 46.2 <0.001
28.5 45.1 ± 27.1 44.5 ± 27.6 0.720
10.9 20.4 ± 11.5 20.0 ± 10.6 0.010
47.8 99.9 ± 48.9 105.2 ± 53.7 <0.001
24 374 ± 216 381 ± 222 0.095
servings of nut consumption (Pearson χ2 test for categorical variables or
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After those subjects with extremes of total energy intake
(n = 153) and those with incomplete dietary data
(lack of food frequency questionnaire) at baseline (n = 78)
had been excluded, 7,216 individuals were available for the
present analysis. The mean age of the participants was 67
years and there were a total of 3,071 men and 4,145
women. Table 1 shows the baseline characteristics of study
participants by frequency of total nut consumption.
Subjects who ate nuts more frequently had lower BMI
and waist circumference, were less likely to smoke, and
were more physically active compared to those who
rarely or never consumed nuts. In the upper category
of nut consumption there were fewer individuals with
type 2 diabetes mellitus or who used antidiabetic and
antihypertensive medication. In addition, frequent nut
consumption was associated with a higher intake of energy,
vegetables, fruit, and fish.
Changes in total nut consumption were +15.95 ± 21.10
g/day (mean ± SD) in the MedDiet supplemented with
nuts, -0.80 ± 16.31 g/day in the MedDiet supplementedTable 2 Hazard ratios of total mortality according to the frequen
Total mortality Never
Frequency of total nut consumption: n = 2,118
All causes of death, % (n) 5.6 (119)
Person-years, n 8,724
Crude model 1 (Referen
Multivariable model 1 1 (Referen
Multivariable model 2 1 (Referen
Multivariable model 3 1 (Referen
Frequency of walnut consumption: n = 2,916
All causes of death, % (n) 5.6 (164)
Person-years, n 12,124
Crude model 1 (Referen
Multivariable model 1 1 (Referen
Multivariable model 2 1 (Referen
Multivariable model 3 1 (Referen
Frequency of consumption of other nuts (excluding walnuts): n = 3,308
All causes of death, % (n) 5.0 (166)
Person-years, n 13,936
Crude model 1 (Referen
Multivariable model 1 1 (Referen
Multivariable model 2 1 (Referen
Multivariable model 3 1 (Referen
One serving of nuts equals 28 g. Cox regression models were used to assess the ris
1 was adjusted for age in years, sex, and intervention group. Model 2 was additiona
former, current smoker), educational level (illiterate/primary education, secondary e
history of diabetes (yes/no), history of hypercholesterolemia (yes/no), use of oral an
of statins (yes/no), and total energy intake (kcal/day). Model 3 was also adjusted for
alcohol intake (continuous, adding a quadratic term) and Mediterranean diet adher
Extremes of total energy intake were excluded.with extra virgin olive oil and −3.12 ± 13.85 g/day in the
control group.
During a median follow-up of 4.8 years, 323 total
deaths, 81 cardiovascular deaths and 130 cancer deaths
occurred. Table 2 shows HRs for total mortality by
frequency of total nut consumption, walnut consumption,
and consumption of other nuts. After adjustments for age,
sex and intervention group (model 1), the subjects who ate
nuts more frequently had a lower risk of total mortality in
all the types of nuts analyzed (P for trend <0.001 for
total nut and walnut consumption, and P = 0.010 for
non-walnut nuts). In fully adjusted models, participants
who consumed total nuts, walnuts, or non-walnut nuts >3
servings per week had significant reductions in total
mortality risk of 39%, 45%, and 34%, respectively, compared
to those who rarely or never consumed nuts. The relation-
ship between nut consumption and total mortality was
linear for all the models (P for trend <0.05), except for the
crude model of nut consumption excluding walnuts.
Those participants who ate total nuts, walnuts or other
nuts (excluding walnuts) >3 servings per week had alsocy of nut consumption (including and not including walnuts)
1 to 3 servings/week >3 servings/week P for trend
n = 2,803 n = 2,295
4.2 (117) 3.8 (87)
12,168 10,185
ce) 0.68 (0.52 to 0.88) 0.60 (0.45 to 0.79) 0.005
ce) 0.68 (0.52 to 0.89) 0.55 (0.41 to 0.73) 0.001
ce) 0.69 (0.53 to 0.91) 0.59 (0.43 to 0.79) 0.005
ce) 0.71 (0.54 to 0.93) 0.61 (0.45 to 0.83) 0.012
n = 2,547 n = 1,753
3.9 (100) 3.4 (59)
11,122 7,825
ce) 0.64 (0.50 to 0.83) 0.54 (0.40 to 0.73) <0.001
ce) 0.66 (0.51 to 0.85) 0.50 (0.37 to 0.68) <0.001
ce) 0.65 (0.50 to 0.84) 0.53 (0.39 to 0.73) <0.001
ce) 0.66 (0.51 to 0.86) 0.55 (0.40 to 0.76) <0.001
n = 2,643 n = 1,265
4.1 (109) 3.8 (48)
11,573 5,566
ce) 0.77 (0.60 to 0.98) 0.71 (0.52 to 0.98) 0.068
ce) 0.75 (0.59 to 0.96) 0.62 (0.44 to 0.86) 0.010
ce) 0.78 (0.61 to 1.00) 0.64 (0.45 to 0.90) 0.021
ce) 0.80 (0.62 to 1.03) 0.66 (0.46 to 0.93) 0.031
k of all-cause mortality by frequency of nut consumption. Multivariable model
lly adjusted for body mass index (BMI) in kg/m2, smoking status (never,
ducation, academic/graduate), leisure time physical activity in MET-min/day,
tidiabetic medication (yes/no), use of antihypertensive medication (yes/no), use
dietary variables in quintiles (vegetables, fruits, red meat, eggs, and fish),
ence (13-point score). All models were stratified by recruitment centre.
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reference category (Table 3). The HR of cardiovascular
mortality in the fully-adjusted model of total nut con-
sumption was 0.45 (95% CI 0.25 to 0.81). Table 4 shows
the HRs for cancer death by frequency of total nut
consumption, walnut consumption and consumption of
other nuts. Subjects in the upper category of total nut
consumption had a significant 40% (95% CI −37% to −98%)
reduction in cancer death, although the P for trend was
non significant.
Figure 1 shows the multivariate adjusted HRs for total
mortality by frequency of total nut consumption and
intervention group. In the three arms of the trial, individ-
uals who consumed nuts >3 servings per week tended to
have a lower risk of mortality than those in the reference
category. Subjects in the upper category of nut con-
sumption at baseline allocated to the MedDiet with
nuts intervention had a significant reduction in total
mortality risk of 63% (95% CI −34% to −78%), while
those allocated to the MedDiet with EVOO and theTable 3 Hazard ratios of cardiovascular mortality according t
including walnuts)
Cardiovascular mortality Never
Frequency of total nut consumption: n = 2,118
Cardiovascular death, % (n) 1.7 (36)
Person-years, n 8,724
Crude model 1 (Referen
Multivariable model 1 1 (Referen
Multivariable model 2 1 (Referen
Multivariable model 3 1 (Referen
Frequency of walnut consumption: n = 2,916
Cardiovascular death, % (n) 1.6 (46)
Person-years, n 12,124
Crude model 1 (Referen
Multivariable model 1 1 (Referen
Multivariable model 2 1 (Referen
Multivariable model 3 1 (Referen
Frequency of consumption of other nuts (excluding walnuts): n = 3,308
Cardiovascular death, % (n) 1.3 (43)
Person-years, n 13,936
Crude model 1 (Referen
Multivariable model 1 1 (Referen
Multivariable model 2 1 (Referen
Multivariable model 3 1 (Referen
One serving of nuts equals 28 g. Cox regression models were used to assess the ris
model 1 was adjusted for age (years), sex, and intervention group. Model 2 was add
smoker), educational level (illiterate/primary education, secondary education, acade
(yes/no), history of hypercholesterolemia (yes/no), use of oral antidiabetic medicatio
and total energy intake (kcal/day). Model 3 was also adjusted for dietary variables i
(continuous, adding a quadratic term) and Mediterranean diet adherence (13-point
energy intake were excluded.control diet had non-significant reductions of 34%
(95% CI −64% to 10%) and 16% (95% CI −52% to 44%),
respectively. The interaction between baseline total
nut consumption and intervention group was signifi-
cant, P = 0.019).
When we used generalized estimating equations to
assess the association between yearly updated measure-
ments of total nut consumption and all-cause mortality
we also found a significant inverse association. The fully-
adjusted relative risk (RR) was 0.68 (95% CI 0.50 to 0.93)
with a significant linear trend test. When we repeated the
analysis to evaluate the association between nut intake and
cardiovascular mortality and cancer mortality the fully-
adjusted relative risk (RR) were 0.76 (95% CI 0.42 to 1.36)
and 0.63 (95% CI 0.39 to 1.03), respectively; however the
linear trend tests were not significant (data not shown).
Discussion
In this longitudinal cohort study of individuals at high
cardiovascular risk with relatively high nut intake living ino the frequency of nut consumption (including and not
1 to 3 servings/week >3 servings/week P for trend
n = 2,803 n = 2,295
0.8 (23) 1.0 (22)
12,168 10,185
ce) 0.44 (0.26 to 0.74) 0.50 (0.29 to 0.85) 0.101
ce) 0.44 (0.26 to 0.76) 0.47 (0.27 to 0.82) 0.075
ce) 0.41 (0.24 to 0.71) 0.41 (0.23 to 0.73) 0.042
ce) 0.42 (0.24 to 0.74) 0.45 (0.25 to 0.81) 0.091
n = 2,547 n = 1,753
0.7 (18) 1.0 (17)
11,122 7,825
ce) 0.41 (0.24 to 0.71) 0.55 (0.31 to 0.96) 0.037
ce) 0.42 (0.24 to 0.74) 0.54 (0.30 to 0.95) 0.040
ce) 0.39 (0.22 to 0.69) 0.49 (0.27 to 0.88) 0.022
ce) 0.41 (0.23 to 0.73) 0.53 (0.29 to 0.98) 0.047
n = 2,643 n = 1,265
1.1 (28) 0.8 (10)
11,573 5,566
ce) 0.76 (0.47 to 1.22) 0.57 (0.28 to 1.13) 0.129
ce) 0.73 (0.45 to 1.20) 0.48 (0.23 to 0.97) 0.056
ce) 0.70 (0.43 to 1.15) 0.40 (0.19 to 0.83) 0.021
ce) 0.74 (0.45 to 1.23) 0.42 (0.20 to 0.89) 0.031
k of cardiovascular mortality by frequency of nut consumption. Multivariable
itionally adjusted for BMI (kg/m2), smoking status (never, former, current
mic/graduate), leisure time physical activity (MET-min/day), history of diabetes
n (yes/no), use of antihypertensive medication (yes/no), use of statins (yes/no),
n quintiles (vegetables, fruits, red meat, eggs, and fish), alcohol intake
score). All models were stratified by recruitment centre. Extremes of total
Table 4 Hazard ratios of cancer mortality according to the frequency of nut consumption (including and not including
walnuts)
Cancer mortality Never 1 to 3 servings/week >3 servings/week P for trend
Frequency of total nut consumption: n = 2,118 n = 2,803 n = 2,295
Cancer death, % (n) 2.1 (44) 1.9 (52) 1.5 (34)
Person-years, n 8,724 12,168 10,185
Crude model 1 (Reference) 0.82 (0.55 to 1.23) 0.64 (0.41 to 1.00) 0.070
Multivariable model 1 1 (Reference) 0.77 (0.51 to 1.16) 0.54 (0.34 to 0.86) 0.015
Multivariable model 2 1 (Reference) 0.79 (0.52 to 1.20) 0.60 (0.37 to 0.96) 0.052
Multivariable model 3 1 (Reference) 0.79 (0.52 to 1.20) 0.60 (0.37 to 0.98) 0.064
Frequency of walnut consumption: n = 2,916 n = 2,547 n = 1,753
Cancer death, % (n) 2.1 (62) 1.9 (48) 1.1 (20)
Person-years, n 12,124 11,122 7,825
Crude model 1 (Reference) 0.82 (0.56 to 1.20) 0.48 (0.29 to 0.80) 0.005
Multivariable model 1 1 (Reference) 0.76 (0.52 to 1.12) 0.41 (0.25 to 0.69) 0.001
Multivariable model 2 1 (Reference) 0.77 (0.52 to 1.14) 0.46 (0.27 to 0.77) 0.003
Multivariable model 3 1 (Reference) 0.76 (0.51 to 1.12) 0.46 (0.27 to 0.79) 0.005
Frequency of consumption of other nuts (excluding walnuts): n = 3,308 n = 2,643 n = 1,265
Cancer death, % (n) 2.0 (66) 1.6 (43) 1.7 (21)
Person-years, n 13,936 11,573 5,566
Crude model 1 (Reference) 0.77 (0.52 to 1.13) 0.79 (0.48 to 1.29) 0.439
Multivariable model 1 1 (Reference) 0.74 (0.50 to 1.10) 0.68 (0.41 to 1.14) 0.213
Multivariable model 2 1 (Reference) 0.79 (0.53 to 1.18) 0.73 (0.43 to 1.23) 0.318
Multivariable model 3 1 (Reference) 0.79 (0.53 to 1.18) 0.75 (0.44 to 1.27) 0.369
One serving of nuts equals 28 g. Cox regression models were used to assess the risk of cancer mortality by frequency of nut consumption. Multivariable model 1
was adjusted for age (years), sex, and intervention group. Model 2 was additionally adjusted for BMI (kg/m2), smoking status (never, former, current smoker),
educational level (illiterate/primary education, secondary education, academic/graduate), leisure time physical activity (MET-min/day), history of diabetes (yes/no),
history of hypercholesterolemia (yes/no), use of oral antidiabetic medication (yes/no), use of antihypertensive medication (yes/no), use of statins (yes/no), and
total energy intake (kcal/day). Model 3 was also adjusted for dietary variables in quintiles (vegetables, fruits, red meat, eggs, and fish), alcohol intake (continuous,
adding a quadratic term) and Mediterranean diet adherence (13-point score). All models were stratified by recruitment centre. Extremes of total energy intake
were excluded.
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tion was inversely related to total mortality after 4.8 years
of follow-up. Compared to non-consumers, subjects who
consumed >3 servings of nuts per week at baseline had a
significant 39% lower risk of all-cause mortality. Relative
risk reductions were similar for the upper baseline category
of non-walnut nuts (34%) or walnut consumption (45%),
and when we evaluated the repeated measurements of total
nut consumption over time (32%).
Moreover, those in the upper category of baseline nut
consumption had a 55% lower risk of cardiovascular
mortality and 40% lower risk of cancer mortality compared
to those who never consumed nuts. The study subjects
participated in the PREDIMED study, a long-term, ran-
domized nutrition intervention trial [14], and those con-
suming more nuts at baseline and allocated to intervention
with a MedDiet supplemented with nuts showed a signifi-
cantly reduced total mortality risk of 63%.
The inverse association between baseline nut consump-
tion and total mortality was of borderline significance inparticipants in the upper category of baseline nut consump-
tion in a MedDiet supplemented with EVOO group, while
there was no significant association in those allocated to a
low-fat control diet, who were advised to reduce intake of
all fatty foods, including nuts. Thus, advice against eating
nuts throughout the study might have counterbalanced
the protective effect of a lifetime intake of these foods. We
assume that the baseline assessment can be considered as
a good correlate of lifetime habits in this population.
Our findings concur with those of epidemiological
studies showing inverse associations between nut consump-
tion and cardiovascular mortality. Four large prospective
studies have reported consistent inverse associations
between nut consumption and fatal CHD or sudden
cardiac death [23–26]. In the Adventist Health Study,
subjects who consumed nuts >5 times per week had a
48% reduced risk of fatal CHD [23]. The reduction in
death from CHD among women who consumed nuts 2 to
4 times/week in the Iowa Women’s Health Study were
57% [24]. However, a later report from the same study
Figure 1 Adjusted hazard ratios of total mortality by frequency of nut consumption and intervention group. The Cox regression models
were adjusted for age in years, sex, BMI in kg/m2, smoking status (never, former, current smoker), educational level (illiterate/primary education,
secondary education, academic/graduate), leisure time physical activity in MET-min/day, history of diabetes (yes/no), history of hypercholesterolemia
(yes/no), use of oral antidiabetic medication (yes/no), use of antihypertensive medication (yes/no), use of statins (yes/no), total energy intake (kcal/d),
dietary variables in quintiles (vegetables, fruits, red meat, eggs and fish), alcohol intake (continuous, adding a quadratic term), and Mediterranean diet
adherence (13-point score). The model was stratified by recruitment centre. Extremes of total energy intake were excluded. Values for the two upper
categories of nut consumption are 0.38 (95% CI: 0.23 to 0.63) and 0.37 (95% CI: 0.22 to 0.66) in the Mediterranean diet supplemented with nuts
(MedDiet + NUTS) group; 0.79 (95% CI: 0.50 to 1.24) and 0.63 (95% CI: 0.36 to 1.1) in the Mediterranean diet supplemented with extra-virgin olive oil
(MedDiet + EVOO) group; and 1.04 (95% CI: 0.64 to 1.69) and 0.84 (95% CI: 0.48 to 1.44) in the low-fat control diet group. P for the interaction between
baseline nut consumption and intervention group= 0.019. P for trend: MedDiet + NUTS, p=0.01; MedDiet + EVOO, p=0.15; Control diet, p=0.42.
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http://www.biomedcentral.com/1741-7015/11/164with longer follow-up failed to confirm that nut con-
sumption protected from CHD death [10]. In addition,
the Nurses’ Health Study observed that women who
consumed nuts ≥5 times/week had a 30% reduced risk
of fatal CHD [25]. Finally, the Physicians’ Health Study
reported a 47% lower risk of sudden cardiac death and
30% lower risk of total CHD death among men who
consumed nuts twice a week or more [7].
In our study, a reduced risk of cancer mortality has
been observed in individuals that frequently consumed
total nuts and walnuts. Few epidemiologic studies have
been conducted evaluating the association between nut
consumption and cancer. An ecological study showed
that prostate cancer mortality was inversely associated
with nuts and oilseed consumption [27]. Moreover, findings
from prospective studies suggest inverse associations
between nut consumption and colorectal or endometrial
cancer, especially in women [28–31]. Some studies showed
inverse associations of nut intake and prostate cancer [32],
however the relationship between nuts and cancer inci-
dence and mortality is insufficient and further research is
needed [33]. A possible explanation that may account for
the inverse relationship between walnuts and cancer mor-
tality but not with other nuts could be that walnuts were
richer in free and total polyphenols than all the other nuts
[34]. As walnuts are usually consumed raw, and roastingcan cause a decline in the efficacy in the antioxidant cap-
acity, it has been shown that raw walnuts, as consumed in
the PREDIMED study, had the highest antioxidant efficacy
among all the nuts [34]; this could play a beneficial role in
the prevention of cancer.
The present results also support those of prior observa-
tional studies suggesting that nut consumption protects
against mortality. In the Iowa Women’s Health Study,
subjects consuming nuts ≥2 times/week had a significant
12% lower mortality risk than those who ate nuts less than
once monthly after a 12-year follow-up [10]. A recent study
from a large Dutch cohort followed for 10 years reported
that men and women in the 75th percentile of nut intake
had 8% and 5% lower risks of all-cause mortality, respect-
ively, compared with subjects in the 25th percentile [11].
Additionally, data from the Nurses’ Health Study, where
participants were followed-up for nearly 18 years, showed
that consuming nuts ≥2 times/week was associated with
a 14% reduced risk of all-cause mortality [12]. It is
noteworthy that the protection against total mortality
afforded by nut consumption in our study was ≥3 orders
of magnitude higher than that observed in studies of
non-Mediterranean populations. A likely reason is that
PREDIMED participants had a rather high self-selected
nut intake before entering the study. Thus, 32% of
PREDIMED participants consumed nuts >3 times/week,
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week in both the Iowa Women’s Health Study [10] and
the Nurses’ Health Study [12]. In the Dutch study, par-
ticipants in the 75th percentile of nut consumption had
rather low average daily intakes of 11.1 g for men and
6.2 g for women [11].
The healthy nutritional profile of nuts may account
for the inverse association observed between nuts and
mortality. Nuts are high in monounsaturated fatty
acids, fiber, minerals, vitamins and many bioactive
compounds; all these nutrients may partly explain the
beneficial effects on health that nuts have been shown
to exert [3,4]. The frequency of nut consumption has
been inversely related to several chronic prevalent con-
ditions, such as diabetes, hyperlipidemia, hypertension,
obesity, metabolic syndrome, cancer, and CHD, among
others [5,26]. These inverse associations can be influenced
by various mechanisms: nuts improve the blood lipid
profile [6] and appear to decrease insulin resistance [8],
and there is also evidence suggesting that they can modu-
late inflammation [35], oxidative stress [36], and endothe-
lial function [37]. As a large body of evidence supports the
beneficial effects of frequent nut consumption on many
health outcomes, it is plausible that nuts protect as well
against all-cause mortality.
Our study has limitations. First, given its observational
nature, it is not possible to firmly conclude that the
inverse relationship between nut consumption and total
mortality reflects cause and effect. Second, even though
data were adjusted for all possible confounders, there is
still the possibility of residual confounding. However, the
enhanced protective effect against all-cause mortality
observed in frequent nut consumers at baseline who
continued eating nuts during follow-up because they
were allocated to the nuts intervention arm supports a
causal relationship between increasing dietary exposure
to nuts and reduced mortality. However, as the study
was conducted in an older Mediterranean population at
high cardiovascular risk, the results cannot easily be
extrapolated to the general population. Nevertheless, it
is relevant to assess these associations in individuals at
high cardiovascular risk because this population is the
most frequently attended by primary care physicians and
the segment of population that can obtain higher bene-
fits with diet or lifestyle changes.
There are also strengths to our study, such as a large
sample size, relatively long duration of follow-up, and
objective and thorough ascertainment of mortality as
outcome in this prospective observational assessment.
Conclusions
In summary, this study provides further evidence of the
inverse relationship between the frequency of nut con-
sumption and the risk of mortality in a Mediterraneanpopulation at high cardiovascular risk with relatively high
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